A Tool to Support Students-to-Teacher Feedback in Asynchronous Online Contexts

In recent years, the world of education has become increasingly Hybrid (online / on location) and Flexible (synchronous / asynchronous). One of the risks of these mixed environments is the distance between teacher and students that can make interaction, a crucial component of the teaching / learning process, more difficult. This paper introduces Evoli, a tool to support the “HyFlex model”; more specifically, the component dealing with online / asynchronous mode. Evoli enables teachers to receive precise, time-stamped feedback by their students on educational materials (typically videos). Students go through the materials and express their level of understanding as well as their questions and comments. Dashboards with the students' data allow the teacher to know, topic by topic, what is clear and what is not and thus how to organize the synchronous sessions. The tool was evaluated in a real-life setting, involving 63 graduate students in a course on Plasma Physics. The students filled in a System Usability Scale questionnaire and some questions regarding the perceived usefulness of the tool; the teacher's opinion was gathered via a semi-structured interview. Results show that students found the tool both usable and useful; the teacher's opinion was that the tool allowed prompting more reactions than a normal setting and an optimization of teaching organization

Does Oxidative Stress Play a Role in the Pathogenesis of Urticarias

Radical oxygen species (ROS) modulate various cellular processes and are involved in physiologic and pathologic conditions, including inflammation. There is growing evidence that supports the existence of an abnormal redox status in some chronic inflammatory skin diseases, including contact dermatitis, atopic dermatitis and psoriasis. This review introduces some general aspects on the role of oxidative stress in cutaneous inflammation, with special emphasis on urticarias, summarizing recent novel findings derived from the study of physical urticarias and chronic idiopathic urticaria

acute allergic reactions to anisakis simplex after ingestion of anchovies

symptoms after ingestion of esh. The etiological role of The study population also comprised 33 controls grouped as: Anisakis simplex was evaluated in 49 adult subjects with ‐ 24 individuals who never ate raw or undercooked esh during acute allergic symptoms after ingestion of anchovies. their lifetime, of whom 5 were non-atopic healthy subjects, Serum-specie c IgE and prick tests to anchovy were nega- 9 were non-atopic patients with physical urticarias, and 10 tive in each patient. Specie c IgE reactions to Anisakis had a personal history of atopy (atopic dermatitis, allergic asthma and/or rhinitis); were positive in 45 patients and skin tests in 43. Only 3 ‐ 9 regular consumers of raw-esh products with no antepatients with allergy to the nematode were atopic. cedents of atopy or any allergic reactions. However, IgE responses to Anisakis were also observed After an adequate washout period from active treatments, in in habitual consumers of raw e sh, without any clinical vivo tests were performed in both patients and controls: manifestations, suggesting that the relevance of results of ‐ skin-prick tests (SPTs) with common aeroallergens conventional tests has to be interpreted on the basis of (Stallergenes Italia, Saronno, Varese, Italy)

Green synthesis of privileged benzimidazole scaffolds using active deep eutectic solvent

The exploitation and use of alternative synthetic methods, in the face of classical procedures that do not conform to the ethics of green chemistry, represent an ever-present problem in the pharmaceutical industry. The procedures for the synthesis of benzimidazoles have become a focus in synthetic organic chemistry, as they are building blocks of strong interest for the development of compounds with pharmacological activity. Various benzimidazole derivatives exhibit important activities such as antimicrobial, antiviral, anti-inflammatory, and analgesic activities, and some of the already synthesized compounds have found very strong applications in medicine praxis. Here we report a selective and sustainable method for the synthesis of 1,2-disubstituted or 2-substituted benzimidazoles, starting from o-phenylenediamine in the presence of different aldehydes. The use of deep eutectic solvent (DES), both as reaction medium and reagent without any external solvent, provides advantages in terms of yields as well as in the work up procedure of the reaction.Fil: Gioia, Maria Luisa Di. Università della Calabria; ItaliaFil: Cassano, Roberta. Università della Calabria; ItaliaFil: Costanzo, Paola. Magna Græcia University. Department of Health Sciences; ItaliaFil: Herrera Cano, Natividad Carolina. Universidad Nacional de Córdoba; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba. Instituto de Ciencia y Tecnología de Alimentos Córdoba. Universidad Nacional de Córdoba. Facultad de Ciencias Químicas. Instituto de Ciencia y Tecnología de Alimentos Córdoba; ArgentinaFil: Maiuolo, Loredana. Università della Calabria; ItaliaFil: Nardi, Monica. Magna Græcia University. Department of Health Sciences; ItaliaFil: Nicoletta, Fiore Pasquale. Università della Calabria; ItaliaFil: Oliverio, Manuela. Magna Græcia University. Department of Health Sciences; ItaliaFil: Procopio, Antonio. Magna Græcia University. Department of Health Sciences; Itali

Cetuximab continuation after first progression in metastatic colorectal cancer (CAPRI-GOIM): A randomized phase II trial of FOLFOX plus cetuximab versus FOLFOX

Background: Cetuximab plus chemotherapy is a first-line treatment option in metastatic KRAS and NRAS wild-type colorectal cancer (CRC) patients. No data are currently available on continuing anti-epidermal growth factor receptor (EGFR) therapy beyond progression. Patients and methods: We did this open-label, 1:1 randomized phase II trial at 25 hospitals in Italy to evaluate the efficacy of cetuximab plus 5-fluorouracil, folinic acid and oxaliplatin (FOLFOX) as second-line treatment of KRAS exon 2 wild-type metastatic CRC patients treated in first line with 5-fluorouracil, folinic acid and irinotecan (FOLFIRI) plus cetuximab. Patients received FOLFOX plus cetuximab (arm A) or FOLFOX (arm B). Primary end point was progressionfree survival (PFS). Tumour tissues were assessed by next-generation sequencing (NGS). This report is the final analysis. Results: Between 1 February 2010 and 28 September 2014, 153 patients were randomized (74 in arm A and 79 in arm B). Median PFS was 6.4 [95% confidence interval (CI) 4.7-8.0] versus 4.5 months (95% CI 3.3-5.7); [hazard ratio (HR), 0.81; 95% CI 0.58-1.12; P = 0.19], respectively. NGS was performed in 117/153 (76.5%) cases; 66/117 patients (34 in arm A and 32 in arm B) had KRAS, NRAS, BRAF and PIK3CA wild-type tumours. For these patients, PFS was longer in the FOLFOX plus cetuximab arm [median 6.9 (95% CI 5.5-8.2) versus 5.3 months (95% CI 3.7-6.9); HR, 0.56 (95% CI 0.33-0.94); P = 0.025]. There was a trend in better overall survival: median 23.7 [(95% CI 19.4-28.0) versus 19.8 months (95% CI 14.9-24.7); HR, 0.57 (95% CI 0.32-1.02); P = 0.056]. Conclusions: Continuing cetuximab treatment in combination with chemotherapy is of potential therapeutic efficacy in molecularly selected patients and should be validated in randomized phase III trials

Chronic pruritus in the absence of specific skin disease: an update on physiopathology, diagnosis and therapy

Chronic pruritus is a major and distressing symptom of many cutaneous and systemic diseases and can significantly impair the patient's quality of life. Pruritus perception is the final result of a complex network involving dedicated nerve pathways and brain areas, and an increasing number of peripheral and central mediators are thought to be involved. Itch is associated with most cutaneous disorders and, in these circumstances, its management overlaps with that of the skin disease. Itch can also occur without associated skin diseases or primary skin lesions, but only with nonspecific lesions secondary to rubbing or scratching. Chronic itch with no or minimal skin changes can be secondary to important diseases, such as neurologic disorders, chronic renal failure, cholestasis, systemic infections, malignancies, and endocrine disorders, and may also result from exposure to some drugs. The search for the cause of pruritus usually requires a meticulous step-by-step assessment involving careful history taking as well as clinical examination and laboratory investigations

Update on subcutaneous methotrexate for inflammatory arthritis and psoriasis

Methotrexate (MTX) is one of the mainstays of treatment for several immune-mediated inflammatory joint and skin diseases, especially rheumatoid arthritis (RA) and moderate-to-severe psoriasis. Oral MTX has been used for the treatment of such diseases for decades for many reasons. There is, however, a relevant interpatient variability of clinical and safety outcomes that can also be related to differences in patients’ individual pharmacogenomic profile. Orally administered MTX has been found to have a saturable intestinal absorption and nonlinear pharmacokinetics, with significant consequences on drug bioavailability and clinical efficacy. The current evidence shows that parenterally administered MTX results in rapid and complete absorption, higher serum levels, and less variable exposure than oral dosing. The use of parenteral MTX, particularly when administered as a subcutaneous (SC) injection, has recently raised great interest in order to overcome the limitations of oral MTX. The effectiveness and safety of SC MTX have mostly been assessed in rheumatological settings, especially in patients with RA. There are only a limited number of data on SC MTX in juvenile idiopathic arthritis and even fewer in psoriatic disease. Various clinical experiences have suggested that SC MTX is more effective than oral MTX and may provide significant benefit even in patients in whom oral MTX proved to be inadequate. The increased efficacy of SC MTX resulting from higher drug exposure compared with oral MTX has been associated with a similar safety profile and in various reports even with a lower frequency of gastrointestinal complaints. The aim of this article was to review the available literature data on SC MTX treatment of inflammatory arthritis, with special emphasis on RA and psoriasis, examining differences with oral MTX treatment. A brief mention of pharmacokinetics, pharmacodynamic features and pharmacoeconomic considerations is also given